Literature DB >> 31391932

CON: Patients With Decompensated Cirrhosis Listed for Liver Transplantation Should Be Treated Posttransplant.

Mark R Pedersen1, Branden D Tarlow2, Arjmand R Mufti1.   

Abstract

Entities:  

Year:  2019        PMID： 31391932      PMCID： PMC6677008          DOI： 10.1002/cld.789

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  12 in total

1.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

2.  Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).

Authors:  G W McCaughan; P A Thwaites; S K Roberts; S I Strasser; J Mitchell; B Morales; S Mason; P Gow; A Wigg; C Tallis; G Jeffrey; J George; A J Thompson; F C Parker; P W Angus
Journal:  Aliment Pharmacol Ther       Date:  2017-12-05       Impact factor: 8.171

3.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Authors:  Michael Charlton; Gregory T Everson; Steven L Flamm; Princy Kumar; Charles Landis; Robert S Brown; Michael W Fried; Norah A Terrault; Jacqueline G O'Leary; Hugo E Vargas; Alexander Kuo; Eugene Schiff; Mark S Sulkowski; Richard Gilroy; Kymberly D Watt; Kimberly Brown; Paul Kwo; Surakit Pungpapong; Kevin M Korenblat; Andrew J Muir; Lewis Teperman; Robert J Fontana; Jill Denning; Sarah Arterburn; Hadas Dvory-Sobol; Theo Brandt-Sarif; Phillip S Pang; John G McHutchison; K Rajender Reddy; Nezam Afdhal
Journal:  Gastroenterology       Date:  2015-05-15       Impact factor: 22.682

4.  Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.

Authors:  Carlos Fernández Carrillo; Sabela Lens; Elba Llop; Juan Manuel Pascasio; Javier Crespo; Juan Arenas; Inmaculada Fernández; Carme Baliellas; José Antonio Carrión; Manuel de la Mata; Maria Buti; Lluís Castells; Agustín Albillos; Manuel Romero; Juan Turnes; Clara Pons; José María Moreno-Planas; José Javier Moreno-Palomares; Conrado Fernández-Rodriguez; Javier García-Samaniego; Martín Prieto; Miguel Fernández Bermejo; Javier Salmerón; Ester Badia; Magdalena Salcedo; José Ignacio Herrero; Rafael Granados; Michel Blé; Zoe Mariño; José Luis Calleja
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

5.  Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.

Authors:  Norah A Terrault; Stefan Zeuzem; Adrian M Di Bisceglie; Joseph K Lim; Paul J Pockros; Lynn M Frazier; Alexander Kuo; Anna S Lok; Mitchell L Shiffman; Ziv Ben Ari; Lucy Akushevich; Monika Vainorius; Mark S Sulkowski; Michael W Fried; David R Nelson
Journal:  Gastroenterology       Date:  2016-08-24       Impact factor: 22.682

6.  Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era.

Authors:  M G Bowring; L M Kucirka; A B Massie; X Luo; A Cameron; M Sulkowski; K Rakestraw; A Gurakar; I Kuo; D L Segev; C M Durand
Journal:  Am J Transplant       Date:  2016-08-24       Impact factor: 8.086

7.  Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.

Authors:  Luca Saverio Belli; Marina Berenguer; Paolo Angelo Cortesi; Mario Strazzabosco; Susanne-Rasoul Rockenschaub; Silvia Martini; Cristina Morelli; Francesca Donato; Riccardo Volpes; Georges-Philippe Pageaux; Audrey Coilly; Stefano Fagiuoli; Giuliana Amaddeo; Giovanni Perricone; Carmen Vinaixa; Gabriela Berlakovich; Rita Facchetti; Wojciech Polak; Paolo Muiesan; Christophe Duvoux
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

8.  Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.

Authors:  Fred Poordad; Eugene R Schiff; John M Vierling; Charles Landis; Robert J Fontana; Rong Yang; Fiona McPhee; Eric A Hughes; Stephanie Noviello; Eugene S Swenson
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

9.  Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort.

Authors:  Sebastian Bernuth; Daniel Grimm; Johanna Vollmar; Felix Darstein; Jens Mittler; Michael Heise; Maria Hoppe-Lotichius; Peter R Galle; Hauke Lang; Tim Zimmermann
Journal:  Drug Des Devel Ther       Date:  2017-07-12       Impact factor: 4.162

10.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.